Evidence map›Paper›PMID 38915247›Full record

ArticleAnalytical chemistry2024

Multicolumn Nanoflow Liquid Chromatography with Accelerated Offline Gradient Generation for Robust and Sensitive Single-Cell Proteome Profiling.

Xiaofeng Xie, Thy Truong, Siqi Huang, S Madisyn Johnston, Simon Hovanski, Abigail Robinson, Kei G I Webber, Hsien-Jung L Lin, Dong-Gi Mun, Akhilesh Pandey and 1 more

Abstract read
In one paragraph

Article in Analytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. SynchroSep-MS: Parallel LC Separations for Multiplexed Proteomics.Journal of the American Society for Mass Spectrometry · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaofeng XieDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
Thy TruongDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
Siqi HuangDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
S Madisyn JohnstonDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
Simon HovanskiDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
Abigail RobinsonDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
Kei G I WebberDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.
Hsien-Jung L LinDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.ORCID 0000-0003-4704-3692
Dong-Gi MunDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, United States.
Akhilesh PandeyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, United States.ORCID 0000-0001-9943-6127
Ryan T KellyDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States.ORCID 0000-0002-3339-4443

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Mayo Clinic Center for Clinical ProteomicsU01CA271410 · NCI · MAYO CLINIC ROCHESTER · PI Rafael Fonseca, AKHILESH PANDEY · 2022 to 2026
$5.3M
SBIR PHASE II, TOPIC 420: INTEGRATED PLATFORM AND CONSUMABLES FOR ROBUST, SENSITIVE AND HIGH-THROUGHPUT SINGLE-CELL PROTEOMICS75N91023C00027 · NCI · MICROMICS TECHNOLOGIES LLC · PI KELLY, RYAN · 2023 to 2023
$2.0M
Advanced Sample Preparation, Separation and Multiplexed Analysis for In-Depth Proteome Profiling of >1000 Single Cells Per DayR01CA279074 · NCI · BRIGHAM YOUNG UNIVERSITY · PI KELLY, RYAN T · 2023 to 2025
$1.6M
Fully automated and ultra-high-throughput platform for in-depth single-cell proteomicsR01GM138931 · NIGMS · BRIGHAM YOUNG UNIVERSITY · PI KELLY, RYAN T · 2020 to 2023
$1.6M
In-depth and label-free proteome profiling of hundreds of single cells per dayR21CA272326 · NCI · BRIGHAM YOUNG UNIVERSITY · PI KELLY, RYAN T · 2022 to 2024
$529k
NCI NIH HHS 75N91023C00027NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA279074NCI NIH HHS R21 CA272326NCI NIH HHS U01 CA271410NIGMS NIH HHS R01 GM138931
6 · The paper itself

Abstract

Peptide separations that combine high sensitivity, robustness, peak capacity, and throughput are essential for extending bottom-up proteomics to smaller samples including single cells. To this end, we have developed a multicolumn nanoLC system with offline gradient generation. One binary pump generates gradients in an accelerated fashion to support multiple analytical columns, and a single trap column interfaces with all analytical columns to reduce required maintenance and simplify troubleshooting. A high degree of parallelization is possible, as one sample undergoes separation while the next sample plus its corresponding mobile phase gradient are transferred into the storage loop and a third sample is loaded into a sample loop. Selective offline elution from the trap column into the sample loop prevents salts and hydrophobic species from entering the analytical column, thus greatly enhancing column lifetime and system robustness. With this design, samples can be analyzed as fast as every 20 min at a flow rate of just 40 nL/min with close to 100% MS utilization time and continuously for as long as several months without column replacement. We utilized the system to analyze the proteomes of single cells from a multiple myeloma cell line upon treatment with the immunomodulatory imide drug lenalidomide.

Indexed as

ProteomeSingle-Cell AnalysisCell Line, TumorChromatography, LiquidHumansLenalidomideMultiple MyelomaNanotechnologyProteomicsThalidomideLenalidomideProteomeThalidomide

Identifiers

PMID38915247
PMCPMC11482043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.